期刊文献+

一氧化氮吸入对肺动脉高压大鼠血压和血浆中血管活性物质水平的影响 被引量:1

The Plasma Concentrations of Endothelin,Atrial Natriuretic Peptide and Calcitonin Gene Related Peptide and Blood Pressure in Rats with Pulmonary Hypertension Influenced by Exogenous Nitric Oxide
下载PDF
导出
摘要 为探讨一氧化氮吸入是否对肺动脉高压的形成和发展具有阻抑作用 ,并进一步探讨血浆中血管活性物质与肺动脉高压形成和发展的关系。将 10 9只大鼠 (实验终结时 10 1只 )分为四组 :对照组腹腔注射生理盐水 ,其它三组腹腔注射野百合碱复制肺动脉高压模型 ,其中预防组同时吸入一氧化氮 ,治疗组第 3周才开始吸入一氧化氧 ,模型组自由呼吸。每隔 1周分别检测血浆中内皮素、心房钠尿肽和降钙素基因相关肽水平 ,测定右心室收缩压和颈动脉平均压。结果发现 ,腹腔内注射野百合碱时右心室收缩压由 1.71± 0 .35kPa升至 2 .35± 0 .4 4kPa ,第 3周末升至 4 .5 6± 0 .6 5kPa ,证明肺动脉高压已经形成。内皮素和心房钠尿肽均随肺动脉压力升高而增加 ,内皮素由 130± 4ng L升至 187± 37ng L ;心房钠尿肽由 172± 2 8ng L升至 2 0 7± 2 7ng L。降钙素基因相关肽则下降 ,由 2 32± 5 7ng L降至 187± 2 3ng L。间断长期吸入一氧化氮后 ,至第 5周末 ,内皮素和心房钠尿肽呈下降趋势 ,前者由模型组的 6 36± 14 8ng L降至预防组的 5 34± 4 4ng L ,后者由模型组的 1111± 2 4 8ng L降至预防组的 772± 14 5ng L ;降钙素基因相关肽则有所升高 ,由模型组的 4 5± 11ng L增至预防组的 80± 16ng L。右心室收缩压则下降 ,由 Aim To observe whether the level of endothelin (ET), atrial natriuretic peptide (ANP) and calcitonin gene related peptide (CGRP) in the plasma of rats with pulmonary hypertension (PH) can be influenced by exogenous nitric oxide. Methods A monocrotaline (MCT) PH model was founded in rat. Exogenous NO were inhaled during the forming and developing of PH. The changes of ET, ANP and CGRP and systolic pressure of right ventricle (RVSP), mean cervical arterial pressure were measured. Results It demonstrated that the RVSP of MCT rats had been elevated since the first week: from 1.71±0.35 kPa to 2.35±0.44 kPa, and (PH) was formed at the time of the third week: 4.56±0.65 kPa, the plasma concentration of ET and ANP in MCT rats were increased along with pulmonary arterial pressure, ET: from 130±4 ng/L, elevated to 187±37 ng/L; ANP: from 172±28 ng/L elevated to 207±27 ng/L at the first week, but CGRP were lowered: from 232±57 ng/L reduced to 187±23 ng/L at the first week. After exogenous NO were inhaled intervally at long term, ET and ANP have the tendency to reduce: ET reduced from 636±148 ng/L to 534±44 ng/L; ANP reduced from 1 111±248 ng/L to 772±145 ng/L. But CGRP increased from 45±11 ng/L to 80±16 ng/L at the fifth week, RVSP lowered from 2.35±0.44 kPa to 2.02±0.29 kPa at the first week. In comparison with control group, there is a significant difference (P<0.05). Conclusions There is a positive significant correlation between the forming and developing of PH and plasma concentration of ET and ANP, but negative significant correlation with CGRP. The methods of interval and long term time of inhaled exogenous NO could not only attenuate the forming of PH and partly prohibit the process and progress of PH, but also had an effect on the formed PH.
出处 《中国动脉硬化杂志》 CAS CSCD 2003年第3期219-222,共4页 Chinese Journal of Arteriosclerosis
关键词 一氧化氮吸入 肺动脉高压 形成过程 大鼠模型 血压 血浆 血管活性物质水平 Pulmonary Hypertension Vaso Active Substance Exogenous Nitric Oxide Rat
  • 相关文献

参考文献12

  • 1[1]Brunner. Cardiac endothelin and big endothelin in right-heart hypertrophy due to monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res, 1999, 44 (1): 197-206
  • 2[2]Okada Mo, Yamashita C, Okada Ma, et al. Role of endothelin-1 inn beagles with dehydromonocrotaline-induced pulmonary hypertension. Circulation, 1995, 92: 114-119
  • 3[3]Ueno M, Miyauchi T, Sakai S, et al. Effects of physiological or pathological pressure load in vivo on myocardial expression of ET-1 and receptors. Am J Physiol, 1999, 277 (5Pt2): R1 321-330
  • 4[4]Mccormack DG, Mak JCW, Coupe MO, et al. Calcitonin gene-related peptide vasodilation of human pulmonary vessels. J App1 Physiol, 1989, 67: 1 265-270
  • 5[5]Bivalacqua TJ, Hyman AL, Kadowits PJ, et al. Role of calcitonin gene-related peptide (CGRP) in chronic hypoxia-induced pulmonary hypertension in the mouse. Influence of gene transfer in vivo. Regul Pept, 2002, 108 (2-3): 129-133
  • 6[6]Lowenstein CJ, Dinerman JL, Snyder SH, et al. Nitric oxide: A physiologic messenger. Ann Intern Med, 1994, 120: 227-237
  • 7[7]Mattocks AR. Toxicity of pyrrolizidine alkaloids. Nature, 1968, 217: 723-728
  • 8[8]Hayashi Y, Hussa JF, Lalich JJ, et al. Cor-pulmonale in rats. Lab Invest, 1967, 16: 875-881
  • 9[9]Bruner LH, Carpenter LJ, Hamlow P, et al. Effect of a mixed function oxidase inducer and inhibitor on monocrotaline pyrrole pneumotoxicity. Toxicol Appl Pharmacol, 1986, 85: 416-427
  • 10[10]Sugita T, Hyers TM, Dauber IM, et al. Lung vessel leak precedes right ventricular hepertrophy in monocrotaline-treated rats. J Appl Physiol, 1983, 54: 371-374

同被引文献25

  • 1姜德建,李元建.非对称性二甲基精氨酸——新的心血管疾病危险因子和药物防治靶点[J].中国动脉硬化杂志,2005,13(3):379-382. 被引量:19
  • 2Pullamsetti S, Kiss L, Ghofrani HA, et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension [ J ]. Faseb J, 2005, 19 (9) : 1 175-177.
  • 3Ulau P, Zakrzewicz D, Kitowska K, et al. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of A DMA [J]. Am J Physiol Lung Cell Mol Physiol, 2007, 292 ( 1 ) : L18-24.
  • 4Cardounel A J, Cui H, Samouilov A, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function [ J ]. J Biol Chem, 2007, 282 (2) : 879 -887.
  • 5Wojciak-Stothard B, Torondel B, Zhao L, et al. Modulation of Racl activity by ADMA/DDAH regulates pulmonary endothelial barrier function [ J ]. Mol Biol Cell, 2009, 20 ( 1 ) : 33-42.
  • 6Wojciak-Stothard B, Torondel B, Tsang LY, et al. The ADMA/DDAH pathway is a critical regulator of endothelial cell motility [ J ]. J Cell Sci, 2007, 120 (Pt 6): 929-942.
  • 7Waschke J, Baumgartner W, Adamson RH, et al. Requirement of Rac activity for maintenance of capillary endothelial barrier properties [ J ]. Am J Physiol Heart Circ Physiol, 2004, 286 ( 1 ) : H394-401.
  • 8Wojciak-Stothard B, Tsang LY, Haworth SG. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells [ J ]. Am J Physiol Lung Cell Mol Physiol, 2005, 2,88 ( 4 ) : L749 -760.
  • 9Martinez F J, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary, fibrosis [ J ]. Ann Intern Med, 2005, 142 ( 12 Pt 1 ) : 963-967.
  • 10Selman M, Thannickal VJ, Pardo A, et al. Idiopathic pulmonary frbrosis: pathogenesis and therapeutic approaches [ J ]. Drugs, 2004, 64 (4) : 405-430.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部